Regulus Therapeutics Inc. (RGLS)

NASDAQ: RGLS · IEX Real-Time Price · USD
1.74
+0.05 (2.66%)
At close: Dec 2, 2022 3:59 PM
1.76
+0.02 (1.44%)
After-hours: Dec 2, 2022 4:32 PM EST
2.66%
Market Cap 28.46M
Revenue (ttm) n/a
Net Income (ttm) -28.66M
Shares Out 14.97M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 20,396
Open 1.73
Previous Close 1.69
Day's Range 1.69 - 1.76
52-Week Range 1.33 - 4
Beta 1.62
Analysts Buy
Price Target 13.01 (+656.4%)
Earnings Date Nov 10, 2022

About RGLS

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a... [Read more]

Industry Biotechnology
IPO Date Oct 4, 2012
CEO Joseph Hagan
Employees 27
Stock Exchange NASDAQ
Ticker Symbol RGLS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for RGLS stock is "Buy." The 12-month stock price forecast is 13.01, which is an increase of 656.40% from the latest price.

Price Target
$13.01
(656.40% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinica...

Additional Preclinical Promotions Round Out Scientific Leadership SAN DIEGO , Nov. 29, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery...

4 days ago - PRNewsWire

Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates

Company announced first patient dosed in its Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Company announced positive top...

3 weeks ago - PRNewsWire

Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call

SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "...

1 month ago - PRNewsWire

Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS84...

SAN DIEGO , Nov. 2, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "...

1 month ago - PRNewsWire

Regulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022

SAN DIEGO , Oct. 27, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

1 month ago - PRNewsWire

Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study

Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.

2 months ago - Zacks Investment Research

Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascendin...

Phase 1b Multiple Ascending Dose (MAD) Study Initiated RGLS8429 in healthy volunteers was well-tolerated with dose-proportional PK Topline data from first cohort of patients with ADPKD anticipated in 1H...

2 months ago - PRNewsWire

Regulus Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO , Sept. 2, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

3 months ago - PRNewsWire

Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

IND accepted and first subject dosed in the Phase 1 Single-Ascending Dose (SAD) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) RGLS8429 granted Orphan Drug D...

3 months ago - PRNewsWire

Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call

SAN DIEGO , Aug. 4, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "...

3 months ago - PRNewsWire

Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dom...

SAN DIEGO , June 21, 2022 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the...

5 months ago - PRNewsWire

Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 ...

SAN DIEGO , June 13, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

5 months ago - PRNewsWire

Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK

SAN DIEGO , June 2, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "...

6 months ago - PRNewsWire

Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO , May 17, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "...

6 months ago - PRNewsWire

7 Penny Stocks With 10x Potential This Year

These penny stocks all have 10x potential or greater during the remainder of 2022. They are risky but relatively straightforward.

Other symbols: FRSXIMPPKTRAMULNOBSV
6 months ago - InvestorPlace

Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates

FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD) On track to initiate Phase 1 study in second quarter 2022 SAN DIEGO, Ma...

6 months ago - PRNewsWire

Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug

The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022.

6 months ago - Zacks Investment Research

Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Trea...

Company remains on track to initiate Phase 1 clinical study in second quarter 2022 SAN DIEGO , May 11, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused ...

6 months ago - PRNewsWire

Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call

SAN DIEGO , May 5, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "C...

6 months ago - PRNewsWire

Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaborati...

- Preliminary data are expected in the second half of 2022 SAN DIEGO , March 24, 2022  /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and ...

8 months ago - PRNewsWire

Regulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Updates

SAN DIEGO, March 10, 2022 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (th...

8 months ago - PRNewsWire

Regulus Therapeutics Announces Timing for Fourth Quarter and Year-End 2021 Financial Results Webcast and Conference Call

SAN DIEGO, March 3, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "...

9 months ago - PRNewsWire

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

SAN DIEGO, Feb. 24, 2022 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

9 months ago - PRNewsWire

Regulus Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 10, 2022 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

9 months ago - PRNewsWire

Regulus (RGLS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Regulus (RGLS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions...

10 months ago - Zacks Investment Research